2020 ASCO GI Cancer Update: Is There a Difference in Survival With FOLFIRINOX vs. Gemcitabine and Abraxane in Pancreatic Adenocarcinoma? Did FGFRi Pemigatinib Show PFS in Cholangiocarcinomas? Do IO Combinations Improve OS vs. Sorafenib in HCC?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ASCO GI Cancer Update: Is There a Difference in Survival With FOLFIRINOX vs. Gemcitabine and Abraxane in Pancreatic Adenocarcinoma? Did FGFRi Pemigatinib Show PFS in Cholangiocarcinomas? Do IO Combinations Improve OS vs. Sorafenib in HCC?

By Penn Medicine 2020 Updates in Oncology FEATURING Jennifer Eads

924 views

July 14, 2020

0 Comments

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl

22:55

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "GI Key Studies Including PROSPECT, HERIZON…

Feat. R. Kim, R. Mehta

10:22

Houston Methodist Hospital

mRNA Vaccine in Treatment of Pancreatic Cancer

Feat. J. Gonzalez

27:37

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini

23:58

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

Feat. R. Kim, R. Mehta

27:04

Fengting Yan

Cancer Screening Molecular Tools

06:47

UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang

26:59

University of Texas Southwestern Medical Center

2023 AASLD Guidance for HCC

Feat. A. Singal

13:47

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Tramet…

Feat. V. Subbiah

07:27

Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

16:40

Moffitt Cancer Center

Year in Review: Hepatobiliary Cancers

Feat. R. Kim, T. Biachi

22:02

ACG 2023 Conference Coverage

ACG 2023 Highlights: HCC Updates - Diagnosis and Management

Feat. R. Wong

19:41

Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

13:58

Insights from 2024 ASCO® GI Annual Meeting

ASCO® GI 2024 Summary: "HCC Key Studies Including EMERALD-1 &am…

Feat. R. Kim, T. Biachi

06:03

Total Health

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Feat. A. Grothey

14:14

Stanford Medicine

HCC: Updates in Management

Feat. R. Dhanasekaran

12:04

Arndt Vogel

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions

03:50

UCLA Health

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Feat. Z. Wainberg

14:54

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "HCC and Cholangiocarcinoma Mini Orals Highl…

Feat. L. Rimassa

28:59

The France Foundation

Evolving Options for the Treatment of HCC With IO and Liver-Directed…

Feat. A. Smolock, B. George

Login

Login

Join VuMedi

2020 ASCO GI Cancer Update: Is There a Difference in Survival With FOLFIRINOX vs. Gemcitabine and Abraxane in Pancreatic Adenocarcinoma? Did FGFRi Pemigatinib Show PFS in Cholangiocarcinomas? Do IO Combinations Improve OS vs. Sorafenib in HCC?

Related Content